Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Coherent (COHR) : Anyone else holding? -- Ignore unavailable to you. Want to Upgrade?

To: JDN who wrote (693)	8/29/1999 7:16:00 AM
From: JDN	Read Replies (1) \| Respond to of 788

HELLO out there. Anybody home? Surprised no comments on recent favorable stock action. Did you all see the press release? JDN Coherent<COHR.O>says therapy given priority status SANTA CLARA, Calif., Aug. 27 (Reuters) - Coherent Inc. on Friday said the U.S. Food and Drug Administration has granted priority review status to a new combination laser and drug therapy for treating the vision illness known as age-related macular degeneration, or AMD. The therapy, called Visudyne, uses Coherent's new OPAL photoactivator laser with the drug verteporferin to treat the wet form of AMD, which is the leading cause of blindness in people over 50 years old in the western hemisphere. Priority status indicates the FDA will review the laser treatment's application for approval within six months, the company said in a statement. Coherent filed the application with QLT PhotoTherapeutics Inc. <QLTI.O> and, if approved, the product will be sold worldwide by CIBA Vision Corp., a unit of health care giant Novartis AG <NOVZn.S>. Coherent is a maker of laser products and services for use in eye care, surgical and other applications.